According to the research report titled ‘Asia Pacific Immunohematology Market Size By Technology, Product, End Use, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2019 – 2026’ available with Market Study Report, Asia-Pacific immunohematology market is anticipated to surpass a valuation of USD 850 million by the year 2026.
 

Factors such as increasing occurrence of diabetes along with technological advancement in immunohematology including introduction of fully automated analyzers in order to ensure fast and accurate results are augmenting the growth of Asia-Pacific immunohematology market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2609885/
 

Moreover, rising innovative product launches coupled with increasing adoption of vitro studies across numerous verticals for blood compatibility testing applications are further stimulating the overall market outlook.
 

Based on product, the report states that analyzers & systems segment reflected 33% of the shares of Asia-Pacific immunohematology market in the year 2019 and is poised to record similar growth in the ensuing years. New launches of innovative products in order to facilitate accurate and efficient outcomes are boosting the expansion of the segment during 2019-2026.
 

With regards to technology, erythrocyte-magnetized technology segment is estimated to account for USD 15.3 million by 2026. Multiple advantages of the technology such as high reliability and detection of ABO-D in mixed field reactions as well as lower rate of non-significant antibodies are boosting the growth of the segment.
 

Moving on to the end-user spectrum of the market, Asia-Pacific immunohematology market from diagnostic laboratories segment is projected to register a robust CAGR of 6.7% over 2019-2026. Rising prevalence of blood disorders coupled with escalating number of blood testing have impelled the adoption of immunohematology instruments, which in turn is positively swaying the market dynamics in the region.
 

Elaborating on the country-level analysis, China immunohematology market is estimated to exhibit a 6.6% CAGR through 2026. Rising occurrence of blood disorders as well as diabetes, predominantly in western China is propelling the market growth. Meanwhile, India is also expected to emerge as a lucrative growth avenue for Asia-Pacific immunohematology market over the analysis timeframe.
 

Key participants of Asia-Pacific immunohematology market are Immucor Inc., F. Hoffmann-La Roche AG (Roche Diagnostics), Hologic Inc., Grifols S.A., Bio-Rad Laboratories Inc., Diagast SAS, Selidis A Bros SA (Antisel), Beckman Coulter Inc., Abbott Laboratories, and Becton, Dickinson and Company (BD).